BMS-777607 Clinical Trials

Size	Price	Qty
5mg	USD 147
50mg	USD 670

Clinical Trials

Multiple clinical trials have evaluated BMS-777607 (also known as ASLAN002) in patients diagnosed with advanced and malignant solid tumors. Sponsored by pharmaceutical companies including Bristol-Myers Squibb and ASLAN Pharmaceuticals, these early-stage evaluations spanned Phase I and Phase I/II studies, including dose-escalation investigations. Currently, all recorded clinical trials assessing this compound have completed recruitment.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT01721148	COMPLETED	Malignant Solid Tumour	ASLAN Pharmaceuticals	2012-10	PHASE1
NCT01721148	Completed	Malignant Solid Tumour	ASLAN Pharmaceuticals	2012-10	Phase 1
NCT00605618	COMPLETED	Advanced Solid Tumors	Bristol-Myers Squibb	2008-03	PHASE1; PHASE2
NCT00605618	Completed	Advanced Solid Tumors	Bristol-Myers Squibb	2008-03	Phase 1\|Phase 2

(data from https://clinicaltrials.gov, updated on 2017-01-25)

Check the BMS-777607 product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

BMS-777607 selectively binds to and inhibits c-Met, Axl, Ron, and Tyro3 kinase receptors, thereby blocking ligand-stimulated c-Met autophosphorylation and suppressing downstream PI3K/Akt and MAPK/ERK signaling pathways to impair tumor cell migration, scattering, and invasion. By suppressing these hepatocyte growth factor-driven oncogenic motility signals, the compound inhibits invasive phenotypes, providing a therapeutic rationale for its clinical evaluation in patients with advanced malignant solid tumors.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).